Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort.

Abstract

Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socio-economic factors. We determined AML incidence in older adults and the impact of socio-economic factors on outcomes. We included 3024 AML patients (1996-2016) identified from a population-based registry. AML incidence in patients ≥60years increased from 11.01 (2001-2005) to 12.76 (2011-2016) per 100000 population. Among 879 patients ≥60years in recent eras (2010-2016), rural residents (<100000 population) were less likely to be assessed by a leukaemia specialist (39% rural, 47% urban, p=.032); no difference was seen for lower (43%, quintile 1-3) vs. higher (47%, quintile 4-5) incomes (p=.235). Similar numbers received induction chemotherapy between residence (16% rural, 18% urban, p=.578) and incomes (17% lower, 17% high, p=1.0). Differences between incomes were seen for hypomethylating agent treatment (14% low, 20% high, p=.041); this was not seen for residence (13% rural, 18% urban, p=.092). Among non-adverse karyotype patients ≥70years, 2-year overall survival was worse for rural (5% rural, 12% urban, p=.006) and lower income (6% low, 15% high, p=.017) patients. AML incidence in older adults is increasing, and outcomes are worse for older rural and low-income residents; these patients face treatment barriers.